Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 16/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17507006 | 0.90 | MAP3K12 (0.55) | MAP3K12 | |
| SCHEMBL17507040 | 0.88 | MAP3K12 (0.52) | MAP3K12 | |
| SCHEMBL17507013 | 0.87 | MAP3K12 (0.61) | MAP3K12NLRP3 | |
| SCHEMBL17507042 | 0.85 | MAP3K12 (0.51) | MAP3K12 | |
| SCHEMBL17507022 | 0.83 | MAP3K12 (0.49) | MAP3K12 | |
| SCHEMBL17507055 | 0.80 | MAP3K12 (0.58) | MAP3K12NLRP3IGF1R | |
| SCHEMBL16220524 | 0.76 | MAP3K12 (0.92) | MAP3K12 | |
| SCHEMBL17507063 | 0.74 | MAP3K12 (0.53) | MAP3K12 | |
| SCHEMBL17507035 | 0.72 | MAP3K12 (0.45) | MAP3K12 | |
| SCHEMBL17507002 | 0.72 | MAP3K12 (0.46) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868720-B2 | C-linked heterocycloaklyl substituted pyrimidines and their uses | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | GENENTECH, INC. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046608-A1 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses | TYMS, DPYD, TYMP | MAP3K12 1825/4885NLRP3 586/4885IGF1R 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.